Aptose Biosciences Inc

Aptose Biosciences — Investor Presentation (July 2024)

20 slides from Aptose Biosciences's investor presentation, Jul 26, 2024

  1. Slide 1: Corporate Presentation: Tuspetinib to Treat Newly Diagnosed AML

    Aptose Precision oncology company developing oral targeted agents to treat hematologic malignancies C o r p o r a t e P r e s e n t a t i o n J u l y 26 , 2024 Tuspetinib to Treat Newly Diagnosed AML

  2. Slide 2: Aptose Disclosure

    Aptose Disclosure 2 This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or invitation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/or ass

  3. Slide 3: Aptose Management Team

    Aptose Management Team William G. Rice, PhD Chairman, President & Chief Executive Officer Rafael Bejar, MD, PhD Sr. VP & Chief Medical Officer KOL, Hematologic Malignancies Fletcher Payne Sr. VP, Chief Financial Officer & Chief Business Officer 3

  4. Slide 4: Tuspetinib Lead Clinical Asset

    4 Tuspetinib Lead Clinical Asset TUS +VEN+HMA triplet is being developed as frontline therapy to treat newly diagnosed AML Frontline triplet clinical data expected 2H 2024 Unmet Need for Superior Frontline (1L) Therapy in AML • Progress made with VEN+HMA (SOC) but unmet needs still exists ‒ Response

  5. Slide 5: Tuspetinib Enhancing Venetoclax Efficacy in Frontline Therapy

    5 Tuspetinib Enhancing Venetoclax Efficacy in Frontline Therapy TUS and VEN mechanistically cooperate to prevent drug resistance FLT3 KIT MCL - 1 PI3K/AKT RAS/ MAPK SYK JAK/STAT TUS VEN BCL - 2i resistance involves mutations in multiple pathways to evade BCL - 2 blockade TUS targets VEN resistance p

  6. Slide 6: Newly Diagnosed AML Patient Journey

    6 Newly Diagnosed AML Intensive Chemotherapy (7+3) Therapeutic Failure Low Intensity Therapy (VEN + HMA) AML Patient Journey | 1L Therapy | Current Standard - of - Care (SOC) lead to therapeutic failure…… Complete Remission HSCT Maintenance Therapy Therapeutic Failure Therapeutic Failure Therapeutic

  7. Slide 7: TUS Fulfills Ideal Profile as 3rd Agent for 1L Triplet

    Solution: TUS Fulfills Ideal Profile as 3 rd Agent for 1L Triplet Proof for Triplets : Addition of a 3 rd Targeted Agent Boosts VEN+HMA Responses in 1L AML Addition of gilteritinib (Gilt) FLT3i to VEN+HMA boosts CR rate to 90% in newly diagnosed FLT3+ AML patients 1 So, What’s the Problem: Current 3

  8. Slide 8: Tuspetinib Triplet Opportunity

    Tuspetinib Triplet Opportunity TUS + VEN + HMA Need a superior 1L therapy that treats more patients, increases survival, is safer, and avoids 1L therapeutic failures AML Patient Journey | 1L Therapy High - Level Overview Tuspetinib - containing triplet can become a new 1L SOC to increase survival •

  9. Slide 9: FDA Requirements for TUS to Enter Frontline Therapy

    FDA Requirements for TUS to Enter Frontline Therapy in Newly Diagnosed AML Tuspetinib has Met the FDA Requirements to Perform the Triplet Pilot Study • Next Step: TUS+VEN+AZA Triplet Study Initiate dosing and collect data from Triplet Pilot Study in Newly Diagnosed AML Patients FDA allowed triplet i

  10. Slide 10: TUS+VEN+AZA Triplet Ph 1/2 Study Design

    TUS+VEN+AZA TRIPLET Ph 1/2 Study: Design, Patient Populations, Dose Selection, Goals Patient Populations │ Approx. 18 - 26 Pts Total │ 50% FLT3 - MUT │ <20% TP53+/CK Trial Goals │ Safety, CR rate, MRD negativity and OS across AML subtypes (FLT3 MUT/WT , TP53 MUT , RAS MUT ) Dose Characterization │ D

  11. Slide 11: Planned Clinical Development Plan, Timelines and Milestones

    Q3 Q4 2024 ASH EHA ASH EHA Triplet Frontline Therapy Newly Diagnosed AML TUS+VEN+HMA Planned Clinical Development Plan, Timelines and Milestones ASH EHA Q1 Q2 Q3 Q4 2025 Q1 Q2 Q3 Q4 2026 TUS+VEN+HMA Ph 1/2 Triplet Study Frontline Therapy for Newly Diagnosed AML Dose Characterization for Ph 2/3 Pivot

  12. Slide 12: Tuspetinib Single Agent and TUS+VEN Doublet Clinical Findings Support Triplet

    Tuspetinib (TUS) Single Agent and TUS+VEN Doublet Clinical Findings Support TUS+VEN+HMA Triplet

  13. Slide 13: TUS Single Agent and TUS+VEN Doublet Study Designs in R/R AML

    TUS Single Agent and TUS+VEN Doublet Study Designs in R/R AML Patients Positions TUS for Combination 1L Therapy to Treat Newly Diagnosed AML Cohort 1: 20 mg QD 2 TUS Single Agent Dose Escalation and Exploration 1 Total n=91 1 Data cut Feb 09, 2024 2 GCSF permitted anytime per protocol Cycle 1 Treatm

  14. Slide 14: Patient Characteristics of Highly Treatment Experienced R/R AML Patients

    14 TUS and TUS+VEN : Patient Characteristics of Highly Treatment Experienced R/R AML Patients WT FLT3 MUT FLT3 Patient Characteristics (n=91) 56 34 2 Patient number n (%) 65.5 (18 - 83) 60 (21 - 84) Median Age Years (Range) 24 (42.9%) 14 (41.2%) Female n (%) 2.4 (1 - 6) 3.3 (1 - 11) Lines prior ther

  15. Slide 15: TUS and TUS+VEN Safe and Well Tolerated in R/R AML

    15 TUS and TUS+VEN Safe and Well Tolerated in Highly Treatment Experienced R/R AML TUS+VEN Doublet TUS Single Agent Related to TUS/VEN, n(%) (n=79) Adverse Events Treatment Emergent AEs Related to VEN Treatment Emergent AEs Related to TUS Treatment Emergent AEs Treatment Related AEs Treatment Emerge

  16. Slide 16: Bone Marrow Blast Reductions and Responses in R/R AML Patients

    TUS Single Agent Treatment Bone Marrow Leukemic Blasts │Percent Change from Baseline Blast Reductions Demonstrate Activity Across 4 Dose Levels Activity in Patients Who Failed Prior - VEN and Prior - FLT3i Note: Blast percent change was calculated as 100 X (the lowest post - baseline bone marrow bla

  17. Slide 17: TUS Single Agent and Doublet Support Development for 1L Triplet Therapy

    TUS Single Agent and TUS+VEN Doublet Support Development for 1L Triplet Therapy TUS+VEN+AZA Protocol is Active TUS + VEN + HMA Phase 1/2 Triplet Study Tuspetinib advancing into a triple drug combination (triplet) of target agents Newly diagnosed AML patients are VEN - naïve, FLT3i - naïve, HMA - naï

  18. Slide 18: Key Opinion Leaders Highly Enthusiastic for TUS+VEN+HMA Triplet

    Key Opinion Leaders (KOLs) highly enthusiastic for TUS+VEN+HMA triplet 18 ‒ Investigators' enthusiasm enrolled the TUS+VEN doublet trial ahead of schedule ‒ KOLs now ramping up TUS+VEN HMA triplet trial in newly diagnosed AML Dr. Naval Daver, MD Anderson Cancer Center AML Drug Combination KOL and Gl

  19. Slide 19: Investment Thesis

    Investment Thesis 2024: EHA ‒ Report TUS Single Agent and TUS+VEN Doublet data in R/R AML supporting TUS+VEN+AZA Triplet trial in newly diagnosed AML 2024: Summer (Q3) ‒ Initiate dosing of TUS+VEN+AZA Triplet in newly diagnosed AML 2024: ASH ‒ Report of CR/MRD/Safety data from TUS+VEN+AZA Triplet pi

  20. Slide 20: Thank you

    Thank you APDTOSE BIOSCIENCES

Aptose Biosciences — Investor Presentation (July 2024) on 6ix